Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 274

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy

Wyman, Ken, Atkins, Michael B., Prieto, Victor, Eton, Omar, McDermott, David F., Hubbard, Francie, Byrnes, Christine, Sanders, Kathleen, Sosman, Jeffrey A. · 2006 · Cancer

Abstract

BACKGROUND: Systemic treatment of metastatic melanoma is largely ineffective and alternative approaches are needed. Imatinib mesylate is an oral tyrosine kinase inhibitor that targets bcr‐Abl, c‐kit, platelet‐derived growth factor receptor (PDGFR)‐α, and PDGFR‐β, leading to remarkable clinical responses in several cancers. Signal transduction via c‐kit, PDGFR‐α, and PDGFR‐β has been demonstrated in malignant melanoma. METHODS: The primary objective of this Phase II study was to determine the response rate, response duration, and the frequency of 6‐month progression‐free survival in patients who could receive up to 2 prior therapeutic regimens. Initially, patients received imatinib at at dose of 400 mg twice orally each day. Based on Simon's optimal design, the study allowed entry of 21 patients; if there were ≥ 2 objective responses, accrual would then continue to a total of 41 patients. RESULTS: Twenty‐six patients were enrolled. Patients experienced 29 episodes of Grade 3 and 2 episodes of Grade 4 toxicity (according to National Cancer Institute common toxicity criteria). No objective clinical responses were noted among the 25 evaluable patients. The median time to progression was 54 days and the median overall survival was 200 days. No patient was free of disease progression at 6 months. Paraffin‐embedded tumor specimens from 15 patients were tested for expression of imatinib responsive kinases by immunohistochemistry. Three tumors had moderate and 5 tumors had weak staining for c‐kit. Five tumor samples had weak staining for PDGFR‐α and ‐β. CONCLUSIONS: Imatinib is an inactive single agent in metastatic melanoma in a population of predominately pretreated patients. The levels of c‐kit and/or PDGFR‐α, ‐β expression in the current study were lower than previously reported. Alternative treatment strategies remain a priority for patients with advanced melanoma. Cancer 2006. © 2006 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.21834

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 274

Metadata

Authors
Wyman, K., Atkins, M. B., Prieto, V., Eton, O., McDermott, D. F., Hubbard, F., Byrnes, C., Sanders, K., & Sosman, J. A.
Venue
Cancer
Publisher
Wiley
Published
2006-03-24
Volume
106
Issue
9
Pages
2005-2011
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2015682571
Cited by
274
References
25
FWCI
9.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy. https://app.cochat.ai/papers/10.1002/cncr.21834
The paper
Wyman, K., Atkins, M. B., Prieto, V., Eton, O., McDermott, D. F., Hubbard, F., Byrnes, C., Sanders, K., & Sosman, J. A. (2006). Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy. Cancer. https://doi.org/10.1002/cncr.21834

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.